InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,004.94
(
0.53%
)
US TECH 100
20,562.30
(
0.10%
)
Dow Jones
44,018.58
(
0.66%
)
Brent Oil
73.70
(
-2.33%
)
Bitcoin
76,881.39
(
1.29%
)
Post# of 253559
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 143360

Wednesday, 06/06/2012 11:50:02 AM

Wednesday, June 06, 2012 11:50:02 AM

Post# of 253559
I hadn't realized that. But they are pretty much obliged to dose according to the label in a trial even if that isn't the de facto standard.

Here is the INCY/LLY abstract:

https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=115194

Looks good to me. Same ballpark as Pfizer's drug tofa on ACR20/50/70. Substantially better performance on DAS28<2.6 (a standard measure of remission) with 37% and 22% for the 4mg and 8mg doses compared with around 10% for the Pfizer drug. It's also once a day rather than tofa's BID.

Peter

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up